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Background: Aclidinium/formoterol is a twice-daily (BID) fixed-dose combination (FDC) in development for chronic
obstructive pulmonary disease (COPD). The efficacy and safety of aclidinium/formoterol versus monotherapy and
placebo in patients with COPD was assessed.
Methods: In this 24-week double-blind, parallel-group, active- and placebo-controlled, multicentre Phase III study,
patients (≥40 years, post-bronchodilator forced expiratory volume in 1 second [FEV1]/forced vital capacity <70%
and FEV1 ≥30% but <80% predicted normal) were randomised 2:2:2:2:1 to aclidinium/formoterol 400/12 μg
(n = 385) or 400/6 μg (n = 381), aclidinium 400 μg (n = 385), formoterol 12 μg (n = 384) or placebo (n = 194) BID via
Genuair®/Pressair®a.
Results: At Week 24, aclidinium/formoterol 400/12 μg and 400/6 μg lead to significant improvements from
baseline in 1-hour post-dose FEV1 versus aclidinium (125 mL [95% CI: 90, 160; p < 0 · 001] and 69 mL [95% CI: 34,
105; p < 0.001], respectively) and trough FEV1 versus formoterol (85 mL [95% CI: 51, 119; p < 0.001] and 53 mL
[95% CI: 19, 87; p < 0.01], respectively; co-primary endpoints). Additionally, aclidinium/formoterol 400/12 μg and
400/6 μg provided significant improvements in Transition Dyspnoea Index (TDI) focal score versus placebo (1.29 units
[95% CI: 0.73, 1.86; p < 0.001] and 1.16 units [95% CI: 0.59, 1.73; p < 0.001], respectively; secondary endpoint). All
treatments were well tolerated, with safety profiles of the FDCs similar to those of placebo and monotherapy.
Conclusions: Both aclidinium/formoterol BID doses significantly improved bronchodilation versus monotherapy,
and dyspnoea versus placebo, with no increase in safety risk. Aclidinium/formoterol may be an effective treatment
for patients with COPD.
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Inhaled long-acting bronchodilators (long-acting β2-ago-
nists [LABAs] and long-acting muscarinic antagonists
[LAMAs]) are recommended as the first choice of treat-
ment for patients with symptomatic chronic obstructive
lung disease (COPD) [1]. LAMAs and LABAs relax air-
way smooth muscle by different mechanisms of action,
and when combined may cause greater bronchodilation
than a single agent [2,3]. A combined LABA/LAMA
is a recommended treatment option in patients with
moderate-to-severe COPD [1]. Although a LAMA and
LABA can be administered together using separate
inhalers (i.e. as a ‘free combination’), this usage is not
common, probably due to the inconvenience of hand-
ling separate devices [4]; delivery of medication with a
single device is always more convenient for the patient.
This has prompted the development of fixed-dose com-
binations (FDCs) of LAMAs and LABAs, such as gly-
copyrronium/indacaterol and umeclidinium/vilanterol,
with the additional potential benefit of improved adher-
ence to therapy [5].
Unlike many other LAMA/LABA FDCs, the combin-
ation of the LAMA aclidinium bromide and the LABA
formoterol fumarate is administered twice daily (BID)
[5-7]. BID dosing may provide a 24-hour profile of lung
function improvements that has the potential to improve
the night-time, early morning and day-time symptoms of
COPD that are common in patients with this condition
[7,8].
This Phase III, randomised study aimed to compare
bronchodilator efficacy, effects on symptoms and health
status, and safety of two doses of aclidinium/formoterol
FDC (400/12 μg and 400/6 μg) BID versus the mono-
therapy components (aclidinium 400 μg and formoterol




The ACLIFORM-COPD study (ClinicalTrials.gov NCT
01462942) was a double-blind, randomised, parallel-
group, active- and placebo-controlled, multicentre study
conducted at 193 centres in 22 countries (see Additional
file 1). The first patient enrolled on 26 October 2011; the
last patient completed 4 January 2013.
Following screening and a 2–3-week run-in period, pa-
tients with stable, moderate-to-severe COPD were rando-
mised 2:2:2:2:1 to 24 weeks of double-blind treatment
with twice-daily aclidinium/formoterol FDC 400/12 μg or
400/6 μg, aclidinium 400 μg, formoterol 12 μg or placebo,
all via a breath-actuated, multiple-dose dry powder inhaler
(Genuair®/Pressair®a; Almirall S.A., Barcelona, Spain).
This study was conducted in accordance with the
Declaration of Helsinki, International Conference onHarmonisation/Good Clinical Practice Guidelines, and
local regulations. The protocol was approved by the
regulatory authority for each country and an independ-
ent ethics committee at each centre (Additional file 1:
Table S1). Patients gave written informed consent.
Randomisation and masking
Randomisation was performed using a centralised inter-
active voice response system on Day 1 (Visit 1), with
stratification by smoking status (smoker or ex-smoker).
Patients were instructed to administer one puff of study
treatment at the same time in the morning (8:00–10:00 am)
and evening (8:00–10:00 pm). Treatment identity was
concealed with identical packaging/appearance and no
odour or colour. Patients received training to use
Genuair®/Pressair® at screening and Visit 1.
Study population and concomitant medication
Male and female patients ≥40 years of age who were
current or former cigarette smokers with a smoking his-
tory ≥10 pack-years and diagnosed with moderate-to-
severe COPD according to GOLD 2010 criteria [9]
(post-bronchodilator forced expiratory volume in 1
second (FEV1)/forced vital capacity (FVC) <70% and
FEV1 ≥30% but <80% of predicted normal value) were
eligible for inclusion (see Additional file 1 for exclusion
criteria).
Inhaled salbutamol (100 μg/puff) was permitted as relief
medication as needed, but discontinued 6 hours before
planned study visits. Patients could continue inhaled corti-
costeroids (ICS) provided treatment was stable ≥4 weeks
pre-screening (see Additional file 1 for additional con-
comitant medications).
Assessments
Study assessments at each visit are outlined in Table 1.
Spirometry (FEV1) was performed pre-dose and up to
3 hours post-dose, with additional spirometry measure-
ments performed in a subset of patients (12-hour
spirometry sub-study; ~20% of the intent-to-treat [ITT]
population).
Dyspnoea was assessed at baseline using the Baseline
Dyspnoea Index (BDI), with changes measured using the
Transition Dyspnoea Index (TDI). Health status was
assessed using St George’s Respiratory Questionnaire
(SGRQ). COPD symptoms (day-time, night-time and
early morning) and relief medication use were recorded
in an electronic diary. Day-time symptoms were assessed
using the EXAcerbations of Chronic obstructive pulmon-
ary disease Tool (EXACT), a 14-item diary completed
every night [10,11]. Additionally, changes in specific
respiratory symptoms (breathlessness, cough and sputum,
and chest symptom domains) were assessed using the
EXACT-Respiratory Symptoms score (E-RS; consisting of
Table 1 Timeline of study assessments
Run-in Double-blind treatment Follow-up
Week -3 to -2 Day 1 Week 1 Week 4 Week 12 Week 18 Week 24 Week 26
Assessment (Screening) (Visit 1)a (Visit 2) (Visit 3) (Visit 4) (Visit 5) (Visit 6) (Visit 7)
Pre-dose spirometryb X X X X X X
Post-dose spirometryc Xd X X X X
BDI/TDIe and SGRQ X X X X
EXACTf X X X X X X X
NT and EM symptomsg X X X X X X X
COPD exacerbations X X X X X X X
12-hour spirometry sub-studyh X X X
AEs X X X X X X X X
Laboratory tests (fasted) X Xi Xi
ECG and blood pressure X Xj Xj Xj Xj Xj
24-hour Holter sub-study X Xk Xk
aRandomisation visit; bTwo sets of manoeuvres were performed during the hour pre-morning-dose; cOne set of manoeuvres was performed at 0.5, 1, 2, and 3 hours
post-morning-dose; dAn additional set of manoeuvres was performed at 5 minutes post-morning-dose; eBDI was used at Day 1, TDI at all other visits; fEXACT was
completed every evening; gNT and EM symptoms were recorded every morning; hAdditional spirometry measurements at 4, 6, 8, 10, and 12 hours post-morning-
dose were performed in a sub-set of patients; iBlood samples were taken pre-morning-dose; jECG and blood pressure were measured pre- and 2-hours post-
morning-dose; k24-hour Holter recordings were started from 5 minutes pre-dose on the morning prior to these visits.
AE, adverse event; BDI, Baseline Dyspnoea Index; COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; EM, early morning; EXACT, EXAcerbations
of Chronic obstructive pulmonary disease Tool; NT, night-time; SGRQ, St George’s Respiratory Questionnaire; TDI, Transition Dyspnoea Index.
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early morning symptoms were assessed using a 14-item
questionnaire completed every morning. COPD exacerba-
tions were additionally assessed by Healthcare Resource
Utilisation (HCRU) (see Additional file 1 for further details
of symptoms assessments).
Safety assessments included recording of adverse
events (AEs), laboratory tests, blood pressure measure-
ments, 12-lead electrocardiograms (ECGs) and 24-hour
12-lead Holter recordings (sub-study, ~20% of the safety
population). Major adverse cardiovascular events (MACE;
a composite of total cardiovascular death, non-fatal myo-
cardial infarction and non-fatal stroke) were evaluated
and classified by an independent, blinded adjudication
committee.
Endpoints
The co-primary endpoints were change from baseline at
Week 24 in 1-hour morning post-dose FEV1 versus
aclidinium 400 μg and morning pre-dose (trough) FEV1
versus formoterol 12 μg; these endpoints were specified
based on European Medicines Agency guidelines and US
Federal Drug Administration regulations, which state
that each drug in a fixed-dose combination must make a
documented contribution within the combination to the
claimed effects [14,15]. Secondary endpoints were TDI
focal score and change from baseline in SGRQ total
score at Week 24 (both versus placebo). Additional effi-
cacy endpoints were change from baseline in FEV1 during
3 hours post-dose, peak FEV1, TDI and SGRQ responders
(% patients achieving the minimum clinically importantdifference [MCID] in TDI [≥1 unit increase] and SGRQ
[≥4 units]); changes from baseline in COPD symptoms
(total EXACT-Respiratory Symptoms [E-RS] score, and
night-time and early morning symptoms scores); rate of
COPD exacerbations (HCRU and EXACT); and change
from baseline in relief medication use.
Statistical analysis
Data were analysed using SAS® Version 9.3. Efficacy
analyses, with the exception of exacerbation rate, were
performed on the ITT population (patients who took ≥1
dose of study medication and had a baseline and ≥1
post-baseline FEV1 assessment). Exacerbations and safety
outcomes were assessed in the safety population (patients
who received ≥1 dose of study medication).
A sample size of 1575 (350 per active treatment; 175
placebo) was estimated to provide ≥90% power to detect
a significant difference of 100 mL between aclidinium/
formoterol FDC and aclidinium in change from baseline
in 1-hour post-dose FEV1 (with standard deviation [SD]
280 mL); 65 mL between aclidinium/formoterol FDC
and formoterol 12 μg in change from baseline in trough
FEV1 (with SD 260 mL); and ≥1 unit difference in TDI
focal score (with SD 3.4 units) and ≥4 unit difference in
SGRQ total score (with SD 12.8 units) between aclidi-
nium/formoterol FDC and placebo at Week 24 using
two-sided tests and adjusting for multiple tests at the
overall significance level of 0.05.
Pulmonary function variables, COPD symptoms (in-
cluding TDI focal score), SGRQ total score and relief
medication use were analysed by means of a mixed model
Singh et al. BMC Pulmonary Medicine 2014, 14:178 Page 4 of 11
http://www.biomedcentral.com/1471-2466/14/178for repeated measures (MMRM), adjusted by age and
baseline value as covariates, and treatment group, sex,
smoking status, visit and treatment group-by-visit
interaction as fixed-effect factors. The MMRM for FEV1
variables was additionally adjusted by screening pre- and
post-bronchodilator (salbutamol) FEV1 as a covariate. Effi-
cacy variable treatment effects and treatment differences
were estimated by least squares (LS) means. Safety out-
comes were analysed descriptively for the safety popula-
tion. Additionally, regression analyses were performed for
exacerbation rate (see Additional file 1).
Results
Of 2443 patients screened, 1729 were included in the
safety analysis set; three patients were excluded from the
ITT population due to missing FEV1 data (Figure 1). In
total, 203 (11.7%) patients discontinued treatment; more
patients in the placebo group withdrew prematurely
(17.5%) compared with active treatments (8.8–13.0%).
The primary reasons for withdrawal were patient request
(4.2%), AEs other than COPD exacerbation (2.9%) and
protocol non-compliance (2.0%).
Demographics and baseline characteristics were similar
across treatment groups (Table 2). Post-bronchodilator
FEV1 was approximately 55% in all treatment groups.
Prior to the study, 19.8% of patients were using ICS as
monotherapy (or in free combination) and 31.8% of
patients were using ICS in fixed-dose combination with a
LABA (Table 2).
Pulmonary function
At Week 24, aclidinium/formoterol FDC 400/12 μg
and 400/6 μg caused significantly greater changes fromFigure 1 Patient disposition. AE, adverse event; FDC, fixed-dose combinabaseline in 1-hour morning post-dose FEV1 compared
with placebo (LS means: 299 mL and 244 mL, respect-
ively; both p < 0.001; Figure 2a). Aclidinium and formo-
terol monotherapies also caused improvements compared
with placebo (LS means: 174 mL and 160 mL, respect-
ively; both p < 0.001; Figure 2a). Figure 2b shows that
these FEV1 changes were significantly greater with both
FDC 400/12 μg and 400/6 μg versus either monotherapy
at all timepoints (LS means at Week 24: 125 mL and
69 mL, respectively, versus aclidinium [both p < 0.001];
139 mL and 84 mL versus formoterol [both p < 0.001]);
the 400/12 μg dose was statistically superior to the
400/6 μg dose at all visits except Week 12 (all p < 0.05).
Aclidinium/formoterol FDC 400/12 μg and 400/6 μg
caused significantly greater changes from baseline in
trough FEV1 at Week 24 compared with placebo (LS
means: 143 mL and 111 mL, respectively; both p < 0.001;
Figure 3a). Aclidinium and formoterol monotherapies
also caused improvements compared with placebo (LS
means: 117 mL [p < 0.001] and 58 mL [p < 0.01], respect-
ively; Figure 3a). Figure 3b shows that these FEV1 changes
were significantly greater with FDC 400/12 μg and
400/6 μg versus formoterol at all timepoints (LS means at
Week 24: 85 mL [p < 0.001] and 53 mL [p < 0.01], respect-
ively). Compared with aclidinium, improvements were
numerically greater with FDC 400/12 μg at all visits and
significantly greater at Weeks 1 and 4.
The onset of action of both FDC doses on Day 1 was
fast, with significant improvements in bronchodilation
versus placebo at 5 minutes post-dose (Additional file 1:
Figure S1). The change in FEV1 over 3 hours post-
dose, peak FEV1 and results of 12-hour spirometry
are presented in Additional file 1. Generally, significanttion of aclidinium/formoterol; prot, protocol.
Table 2 Patient demographics and baseline characteristics (safety population)
Placebo FDC FDC Aclidinium Formoterol Total
400/12 μg 400/6 μg 400 μg 12 μg
Patients, n 194 385 381 385 384 1729
Age, years 64.2 ± 8.0 62.7 ± 8.1 62.9 ± 7.7 63.1 ± 8.2 63.4 ± 7.8 63.2 ± 8.0
Males, n (%) 138 (71.1) 261 (67.8) 259 (68.0) 256 (66.5) 255 (66.4) 1169 (67.6)
Caucasians, n (%) 183 (94.3) 367 (95.3) 366 (96.1) 363 (94.3) 362 (94.3) 1641 (94.9)
Current smoker, n (%) 94 (48.5) 181 (47.0) 182 (47.8) 182 (47.3) 179 (46.6) 818 (47.3)
Severity of airflow obstruction, n (%), based on GOLD 2010 criteriaa
Moderate 116 (60.1) 229 (59.5) 230 (60.4) 226 (58.9) 237 (61.9) 1038 (60.1)
Severe 77 (39.9) 156 (40.5) 151 (39.6) 157 (40.9) 144 (37.6) 685 (39.7)
Baseline FEV1, L 1.42 ± 0.54 1.42 ± 0.49 1.41 ± 0.48 1.40 ± 0.51 1.40 ± 0.48 1.41 ± 0.50
Post-bronchodilator FEV1, % predicted 55.0 ± 13.4 54.6 ± 13.1 54.1 ± 13.0 53.6 ± 13.0 54.5 ± 13.2 54.3 ± 13.1
Patients meeting bronchial reversibility criteria, n (%)b 66 (34.0) 134 (34.8) 127 (33.3) 125 (32.6) 114 (29.8) 566 (32.8)
Prior COPD medication, n (%)
Any COPD-related medication 167 (86.1) 330 (85.7) 331 (86.9) 337 (87.5) 329 (85.7) 1494 (86.4)
LABA + ICSc 63 (32.5) 118 (30.6) 128 (33.6) 121 (31.4) 119 (31.0) 549 (31.8)
LAMA 60 (30.9) 118 (30.6) 122 (32.0) 107 (27.8) 110 (28.6) 517 (29.9)
LABA 38 (19.6) 79 (20.5) 69 (18.1) 78 (20.3) 80 (20.8) 344 (19.9)
ICS 39 (20.1) 85 (22.1) 72 (18.9) 79 (20.5) 68 (17.7) 343 (19.8)
BDI focal score 6.6 ± 2.0 6.6 ± 2.1 6.6 ± 2.0 6.5 ± 2.0 6.5 ± 2.1 6.5 ± 2.1
SGRQ total score 45.8 ± 17.6 46.1 ± 17.9 46.7 ± 17.6 46.8 ± 16.8 45.2 ± 18.2 46.2 ± 17.6
aOne patient randomised to formoterol 12 μg had mild COPD at baseline; one patient each randomised to formoterol 12 μg and aclidinium 400 μg had very
severe COPD at baseline; bBronchial reversibility ≥12% and change in FEV1 from pre-test ≥200 mL;
cLABA and ICS in fixed-dose combination.
Data are presented as mean ± SD, unless otherwise stated.
BDI, Baseline Dyspnoea Index; COPD, chronic obstructive pulmonary disease; FDC, aclidinium/formoterol fixed-dose combination; FEV1, forced expiratory volume in
1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; LABA, long-acting β2-adrenergic agonist; LAMA, long-acting
muscarinic antagonist; SD, standard deviation; SGRQ, St George’s Respiratory Questionnaire.
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FDC at all visits compared with placebo and one or both
monotherapies.
Symptoms
At Week 24, both FDC doses caused clinically significant
improvements (≥1 unit) in TDI focal score versus
placebo (400/12 μg: 1.29 units and 400/6 μg: 1.16 units;
both p < 0.001; Figure 4). Aclidinium and formoterol
monotherapies caused significant improvements (both
p < 0.005) versus placebo at Week 24 that fell just below
the 1-unit threshold. The differences between both
FDC doses versus the monotherapies were not sta-
tistically significant (Additional file 1: Table S2). A
significantly higher proportion of FDC-treated and
monotherapy-treated patients had ≥1 unit improvement
in TDI focal score at Week 24 versus placebo (Additional
file 1: Table S2).
The improvements in overall E-RS symptoms with both
FDC doses were significantly greater compared with the
monotherapies and placebo (all comparisons p < 0.05);
changes from baseline in night-time and early morning
symptoms scores followed a similar pattern, althoughnot all comparisons reached statistical significance
(see Additional file 1).
COPD exacerbations data are presented in Additional
file 1. The rate of HCRU exacerbations was low across
treatment arms (0.26–0.41 per patient per year) and
although the rate was numerically lower with both FDC
doses compared with placebo, this difference was not
statistically significant. When assessed with EXACT,
higher exacerbation rates were observed (1.09–1.54 per
patient per year) and the FDC 400/12 μg dose signifi-
cantly reduced the rate of exacerbations compared with
placebo (see Additional file 1: Table S3). During the 24
treatment weeks, the number of patients hospitalised
due to exacerbations (based on HCRU data) was low
and similar between treatment groups (placebo: n = 5
[2.6%]; FDC 400/12 μg: n = 4 [1.0%]; FDC 400/6 μg:
n = 3 [0.8%]; aclidinium 400 μg: n = 7 [1.8%]; formoterol
12 μg: n = 1 [0.3%]).
Health-related quality of life
At Week 24, all active treatments were associated with im-
provements in mean SGRQ total score >4 units (Figure 5);
however, there was a very high placebo response and
a)
b)
Figure 2 Mean treatment differences for change from baseline in 1-hour post-dose FEV1. (a) At Week 24; (b) Over 24 weeks; Data are
presented as least squares means (SE) for the ITT population. ***p < 0.001 vs placebo; ‡p < 0.05; ‡‡‡p < 0.001 vs aclidinium; †††p < 0.001 vs
formoterol; §p < 0.05; §§p < 0.01 vs FDC 400/6 μg. FDC, aclidinium/formoterol fixed-dose combination; FEV1, forced expiratory volume in 1 second;
ITT, intent-to-treat; SE, standard error.
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tween active and placebo treatments (Additional file 1:
Table S2). A significantly higher proportion of patients
receiving FDC 400/6 μg had ≥4 units decrease in SGRQ
total score at Week 24 versus placebo (see Additional
file 1).Relief medication use
Mean treatment differences in overall daily use of
relief medication versus placebo were -0.66 with FDC
400/12 μg (p < 0.001) and -0.73 with 400/6 μg (p < 0.001).
These changes from baseline with both FDC doses
were significantly greater than aclidinium monotherapy
(both p < 0.05), but not compared with formoterol
monotherapy.Safety
The incidence of treatment-emergent AEs (TEAEs) was
similar across study arms (Table 3, also see Additional
file 1). The proportion of patients experiencing a ser-
ious AE (SAE) was low (4.8%) and comparable betweentreatment groups (Table 3). The most frequently reported
SAE was COPD exacerbation (Table 3).
The incidence of MACE was low and comparable
across all study arms (see Additional file 1). TEAEs as-
sociated with anticholinergic or β2-adrenergic activity
generally occurred in <3% of patients in any treatment
group. The exception was headache (β2-adrenergic TEAE),
reported in 7.1%–11.2% of patients. There were four fatal
TEAEs (see Additional file 1); none were considered re-
lated to study medication. There were no clinically signifi-
cant differences between treatment groups in clinical
laboratory tests, vital signs and ECGs (including 24-hour
Holter ECG monitoring; Additional file 1: Table S4).
There were four fatal TEAEs: one in the aclidinium/
formoterol 400/12 μg group (COPD exacerbation), two
in the aclidinium/formoterol 400/6 μg group (COPD
exacerbation [n = 1] and cardiac failure [n = 1]) and one
in the formoterol 12 μg group (cardiac failure). None of
these were considered to be related to study medication
and all four patients had multiple underlying comorbidi-




Figure 3 Mean treatment differences for change from baseline in trough FEV1. (a) At Week 24; (b) Over 24 weeks; Data are presented as
least squares means (SE) for the ITT population. **p < 0.01; *** p < 0.001 vs placebo; ‡p < 0.05 vs aclidinium; ††p < 0.01; †††p < 0.001 vs formoterol.
FDC, aclidinium/formoterol fixed-dose combination of aclidinium/formoterol; FEV1, forced expiratory volume in 1 second; ITT, intent-to-treat; SE,
standard error.
Figure 4 Improvement in TDI focal score at 24 weeks (ITT population). Data are presented as least squares means (SE). ***p < 0.001 vs
placebo. FDC, aclidinium/formoterol fixed-dose combination; ITT, intent-to-treat; MCID, minimum clinically important difference; SE, standard error;
TDI, transition dyspnoea index.
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Figure 5 Change from baseline in SGRQ total score at 24 weeks (ITT population). Data are presented as least squares means (SE). FDC,
aclidinium/formoterol fixed-dose combination; ITT, intent-to-treat; MCID, minimum clinically important difference; SE, standard error; SGRQ, St
George’s Respiratory Questionnaire.
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Both doses of aclidinium/formoterol FDC BID signi-
ficantly improved pulmonary function after 24 weeks
compared to the monotherapy components and placebo
in patients with moderate-to-severe COPD. The greatest
improvements were seen with the higher aclidinium/
formoterol FDC dose. Clinical benefits with aclidinium/Table 3 Number (%) of patients with TEAEs, TESAEs and disco
n (%)
Any TEAE














TEAEs leading to discontinuation
TESAEs
TESAEs occurring in >2 patients in any treatment group (by preferred term)
COPD exacerbation
Pneumonia
COPD, chronic obstructive pulmonary disease; FDC, aclidinium/formoterol fixed-dos
emergent serious adverse event; URTI, upper respiratory tract infection.formoterol FDC were achieved without an increased
risk of AEs.
The pre-defined co-primary endpoints in this study
were chosen to test the individual contributions of
the component therapies, i.e. rapid-onset bronchodila-
tion with formoterol (change from baseline in FEV1
at 1-hour post-morning dose) [5,16,17], and 24-hourntinuations (safety population)
Placebo
FDC FDC Aclidinium Formoterol
400/12 μg 400/6 μg 400 μg 12 μg
(n = 194) (n = 385) (n = 381) (n = 385) (n = 384)
103 (53.1) 194 (50.4) 193 (50.7) 190 (49.4) 217 (56.5)
27 (13.9) 36 (9.4) 38 (10.0) 46 (11.9) 60 (15.6)
16 (8.2) 29 (7.5) 27 (7.1) 35 (9.1) 43 (11.2)
14 (7.2) 30 (7.8) 30 (7.9) 22 (5.7) 26 (6.8)
9 (4.6) 18 (4.7) 13 (3.4) 20 (5.2) 19 (4.9)
5 (2.6) 6 (1.6) 5 (1.3) 2 (0.5) 6 (1.6)
5 (2.6) 3 (0.8) 4 (1.0) 4 (1.0) 1 (0.3)
4 (2.1) 2 (0.5) 3 (0.8) 4 (1.0) 6 (1.6)
3 (1.5) 6 (1.6) 3 (0.8) 3 (0.8) 12 (3.1)
3 (1.5) 8 (2.1) 4 (1.0) 7 (1.8) 10 (2.6)
2 (1.0) 3 (0.8) 4 (1.0) 2 (0.5) 9 (2.3)
1 (0.5) 3 (0.8) 10 (2.6) 3 (0.8) 3 (0.8)
1 (0.5) 2 (0.5) 6 (1.6) 2 (0.5) 10 (2.6)
1 (0.5) 10 (2.6) 2 (0.5) 5 (1.3) 2 (0.5)
8 (4.1) 16 (4.2) 12 (3.1) 17 (4.4) 14 (3.6)
12 (6.2) 23 (6.0) 18 (4.7) 16 (4.2) 14 (3.6)
5 (2.6) 4 (1.0) 4 (1.0) 7 (1.8) 1 (0.3)
1 (0.5) 3 (0.8) 4 (1.0) 0 (0.0) 0 (0.0)
e combination; TEAE, treatment-emergent adverse event; TESAE, treatment-
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baseline in trough FEV1) [18,19]. Both doses of aclidi-
nium/formoterol FDC met both co-primary endpoints,
suggesting that aclidinium/formoterol FDC provides bron-
chodilation that is faster in onset than aclidinium and of a
greater magnitude over the dosing interval than formo-
terol. To date, all LAMA/LABA FDCs have demonstrated
superiority to their monocomponents for improvements
in FEV1, and our study shows similar results [20-24].
Taken together, the results provide good evidence that
LAMA/LABA FDCs deliver additional clinical benefits
versus monotherapy. Currently, there is no established
MCID in bronchodilation for combination therapies
versus their monotherapy components [25]. In this
study, the treatment differences versus monotherapy
were generally greater with the 400/12 μg dose com-
pared with the 400/6 μg dose for bronchodilation end-
points (change from baseline in 1-hour post-dose FEV1,
trough and peak FEV1, FEV1 over 3 hours post-dose
and normalised FEV1 AUC0-12).
Both aclidinium/formoterol FDC doses improved trough
FEV1 by >100 mL compared with placebo; this threshold
is a clinically meaningful change [26]. The contribution of
aclidinium to the increase from baseline in trough FEV1
seen with aclidinium/formoterol 400/12 μg (85 mL versus
formoterol) is within the range observed for the mo-
nocomponents of other LAMA/LABA combinations
(70–95 mL versus LABA) [21,22]. However, caution
should be applied when comparing effect sizes between
studies and head-to-head studies are required for more
meaningful comparisons.
Both aclidinium/formoterol FDC doses provided clin-
ically meaningful (≥1 unit) improvements in TDI focal
score versus placebo with more patients achieving a
≥1-unit improvement. The change in TDI in the placebo
group makes comparisons of the change versus placebo
difficult; however, the magnitude of change in the
placebo group (1.2 units) is the same as that observed in
other studies [21,22] and the changes from baseline of
2.5 and 2.4 units for FDC 400/12 μg and 400/6 μg,
respectively, clearly exceed the MCID. The magnitude of
improvement was numerically greater than that seen
with both monotherapies, although the study was not
powered to detect differences between aclidinium/for-
moterol FDC and monotherapy for TDI or SGRQ. Much
of the data for MCID in TDI focal score and SGRQ total
score has been reported from placebo-controlled trials,
where the treatment effects can be large; for studies in-
vestigating the incremental gain from adding one active
treatment on top of another, it is likely that the treat-
ment effects will be smaller than the differences between
monotherapies and placebo [25].
A ‘Hawthorne effect’ often occurs in COPD trials where-
by patients treated with placebo improve by participatingin a clinical study [27], particularly in countries where
healthcare is not free or easily accessible. However, the
SGRQ total score improvement observed in the placebo
group (-6.5 units) was considerably larger than that ob-
served in most other COPD clinical trials; a meta-analysis
of long-acting bronchodilator COPD trials showed the pla-
cebo effect on SGRQ to be typically 2 units, with no stud-
ies demonstrating increases of >5 units [28]. The large and
mostly unexplained placebo effect that we observed re-
sulted in neither aclidinium/formoterol FDC dose, causing
significantly greater SGRQ improvements compared with
placebo, despite producing large changes from baseline.
However, responder analysis based on the proportion
with ≥4-unit improvement did show a benefit with FDC
400/6 μg. Post-hoc analyses showed that ~90% of pa-
tients were randomised during winter/spring and treat-
ment continued into the spring/summer period when
exacerbation rates are lower [29]; this probably contrib-
uted to the low exacerbation rate in the study and large
improvement in health status in the placebo arm.
Patients with COPD often report a range of symptoms
during normal sleeping hours and on waking [30], and
early morning has been reported as the time of day
when COPD symptoms are most troublesome [8]. Total
daily symptom scores, assessed using the recently vali-
dated E-RS questionnaire [12,13], were significantly
lower with aclidinium/formoterol FDC versus placebo
and both monotherapies. In addition, night-time and
early morning symptoms were improved with aclidinium/
formoterol FDC versus placebo and aclidinium. Aclidi-
nium twice-daily has been shown to improve night-time
and early morning symptoms [18] and our results suggest
that aclidinium/formoterol FDC 400/12 μg provides
greater improvements across the whole 24 hours than
aclidinium monotherapy.
Both aclidinium/formoterol FDC doses were well
tolerated. There was no evidence for additive AEs when
combining the two different drugs and no evidence of
an increase in AEs at the higher FDC dose. These safety
data are consistent with the fact that formoterol is a
well-tolerated drug [31] and aclidinium has low systemic
exposure, minimising the potential for typical LAMA
side effects [32,33]. Furthermore, the 24-hour Holter-
monitoring showed no evidence that aclidinium/formo-
terol FDC increased ECG abnormalities compared with
placebo.
Conclusions
The twice-daily LAMA/LABA aclidinium/formoterol
FDCs had a rapid and sustained effect on lung function,
with significant improvements in bronchodilation com-
pared with monotherapy and COPD symptoms compared
with placebo. Overall, the benefits seen with aclidinium/
formoterol FDC 400/12 μg were greater than those seen
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http://www.biomedcentral.com/1471-2466/14/178with the 400/6 μg dose. Both doses were well tolerated
and had similar safety profiles to placebo. These results
suggest that aclidinium/formoterol FDC may be an effect-
ive new treatment option as a dual bronchodilator for
patients with moderate-to-severe COPD.
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